Search

everythinglearnresearchcommunity

for

Search:↓

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The conversation humorously suggests that drug use might be more effective for hair retention than traditional treatments like minoxidil or finasteride. It attributes full heads of hair in homeless individuals to lifestyle factors like reduced stress or hormonal changes.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

The conversation discusses the conflicting information about Zinc's effect on DHT and its role in hair loss. It mentions that Zinc can act as a 5AR inhibitor at high doses but may increase DHT if taken to correct a deficiency, and highlights the importance of nutritional balance for hair health.

The half-life of Dutasteride is commonly stated as around 5 weeks, but some sources suggest it is 170 hours for men aged 20–49, with further information indicating it varies from 3 days to 5 weeks depending on the dose. The user is seeking clarity on these conflicting figures.

A female user with chronic anemia and vitamin deficiencies is experiencing finer, straighter hair and seeks recommendations for scalp products to improve circulation and prevent potential hair thinning. She is considering growth oils but is unsure of their effectiveness.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

The conversation is about experimenting with topical Viagra or Cialis for hair loss, including methods for dissolving the tablets. The user is also using herbal oil massages and considering using Ethanol/Propylene Glycol for better dissolution.

Finasteride and Dutasteride do not cause dry eyes by damaging meibomian glands, as these glands continue to function normally even when DHT is blocked. Some users report dry eyes with these medications, but others suggest supplements like Omega-3 or krill oil as potential remedies.

A user experimented with applying pure rosemary oil to a single hair strand twice daily, observing increased thickness and pigmentation, but questioned if the oil or the application method caused the change. Some users noted rosemary oil might be as effective as 2% minoxidil for hair growth, though others warned about potential harm from using undiluted oil.

Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.

Topical finasteride can be as effective as oral finasteride for hair regrowth with fewer systemic side effects, but precise dosing is essential. Combining oral dutasteride with topical finasteride is not recommended due to dutasteride's stronger inhibition.

A 29-year-old male shares his 3-month hair regrowth progress using finasteride, minoxidil, and microneedling, reporting no side effects and light initial shedding. He is encouraged by the results and plans to continue the treatment.

A 27-year-old woman with androgenic alopecia is losing hair despite using oral minoxidil and spironolactone, and is considering dutasteride. She is exploring causes like stress and medication side effects, planning tests, and considering treatment changes.

The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.

Aspirin reduces the effectiveness of minoxidil for hair loss. Quercetin and 5-ASA medications also inhibit the necessary enzyme for minoxidil to work.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

Topical Dutasteride may halt hair loss and effectively treat androgenic alopecia. Combining low-dose oral Dutasteride with topical application could maximize regrowth and minimize side effects.

The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.